Sep

01

What we owe to the talent that stays

Below are some quick reflections from Bogdan, one of our founders, who previously worked as a drug discovery scientist. A

Sep 1, 2026

3 min read

Aug

06

The China panic is aimed at the wrong target

A biotech founder in Cambridge or San Francisco can now generate their drug's first human data in a

Aug 6, 2026

4 min read

Jul

22

Where intelligence actually pays off in biopharma

At a biopharma we work with, there's a CRO that runs a particular assay the company orders many

Jul 22, 2026

4 min read

Jul

15

Your biopharma agent isn't your colleague

When we talk to customers about what an agent should be allowed to do in their workspace, the most common

Jul 15, 2026

7 min read

Jul

02

The redacted notebook problem

Somewhere in the world right now, a scientist is taking a photograph of a paper lab notebook, uploading the image

Jul 2, 2026

4 min read

Jun

17

Off-the-record with biotech leaders

Biotech outcomes are binary and milestone-gated, and the math on that doesn't really have a gradient: if

Jun 17, 2026

5 min read

May

27

Building the platform of the future

When we started building Kaleidoscope, we didn’t set out to build an end-to-end platform. Our initial observation

May 27, 2026

3 min read

Apr

30

When setup takes a week but the PO takes six months

In the last few weeks, three separate prospects reached out to us in what looked like sudden bursts of interest.

Apr 30, 2026

4 min read

Apr

08

AI can’t reason with context it doesn’t have

A question we hear often from biopharma leadership and investors: "With AI improving this fast, do we really need

Apr 8, 2026

2 min read

Mar

11

The biggest barrier to modernizing biopharma?

There's a harmful posture across biopharma that is hampering meaningful progress: a belief that certain categories of work

Mar 11, 2026

5 min read